COMP <GO>
NEO vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
NeoGenomics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NEO 0
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $17.93 (-0.33%) • MKT CAP: $2.32B
roic
-9.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 43.20% | 70.20% | -27.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -9.00% | 29.00% | -38.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 3.47% | -4.41 | ABBV | /fcf-yield <GO> |
| Operating Margin | -15.90% | 24.60% | -40.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -14.80% | 6.90% | -21.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.72 | 5.33 | -2.61 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 65.1 | -14.13 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.32B | $513.86B | -$511.54B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEO REV | ABBV REV | NEO GROSS % | ABBV GROSS % | NEO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $727.3M | $61.16B | 43.2% | 70.2% | -$21.8M | $17.82B |
| FY 2024 | $660.6M | $56.33B | 43.9% | 70.0% | -$34.0M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$2.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEO // BETA —
ABBV // BETA 1.15